[
    [
        {
            "time": "2020-07-22",
            "orginal_text": "基金持仓分析：权益仓位提高 增配科技、消费、医药",
            "features": {
                "keywords": [
                    "基金",
                    "持仓",
                    "权益",
                    "科技",
                    "消费",
                    "医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "消费",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "基金持仓分析：权益仓位提高 增配科技、消费、医药",
            "scores": {
                "News_content": "基金持仓分析：权益仓位提高 增配科技、消费、医药",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "药明康德（603259）：中报业绩超预期 长期发展潜力充足",
            "features": {
                "keywords": [
                    "药明康德",
                    "中报",
                    "业绩",
                    "超预期",
                    "长期发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德（603259）：中报业绩超预期 长期发展潜力充足",
            "scores": {
                "News_content": "药明康德（603259）：中报业绩超预期 长期发展潜力充足",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
            "features": {
                "keywords": [
                    "药企",
                    "半年报",
                    "康泰生物",
                    "药明康德",
                    "华海药业",
                    "增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
            "scores": {
                "News_content": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "牛股频频出没！高瓴押注CRO背后的考量",
            "features": {
                "keywords": [
                    "牛股",
                    "高瓴",
                    "CRO",
                    "押注"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "牛股频频出没！高瓴押注CRO背后的考量",
            "scores": {
                "News_content": "牛股频频出没！高瓴押注CRO背后的考量",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "药明康德（603259）：核心业务二季度超预期增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "核心业务",
                    "二季度",
                    "超预期",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德（603259）：核心业务二季度超预期增长",
            "scores": {
                "News_content": "药明康德（603259）：核心业务二季度超预期增长",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "招商香港：产能持续扩张将巩固药明康德（02359-HK）长期的增长前景重申买入评级",
            "features": {
                "keywords": [
                    "招商香港",
                    "产能扩张",
                    "药明康德",
                    "增长前景",
                    "买入评级"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "招商香港：产能持续扩张将巩固药明康德（02359-HK）长期的增长前景重申买入评级",
            "scores": {
                "News_content": "招商香港：产能持续扩张将巩固药明康德（02359-HK）长期的增长前景重申买入评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "药明康德的AB面：业绩大增股价走高，高管却逢高套现，股东二度减持抛近25亿减持计划 减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩",
                    "股价",
                    "高管",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德的AB面：业绩大增股价走高，高管却逢高套现，股东二度减持抛近25亿减持计划 减持股份",
            "scores": {
                "News_content": "药明康德的AB面：业绩大增股价走高，高管却逢高套现，股东二度减持抛近25亿减持计划 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "制药股普遍获资金青睐 石药集团上扬2%联邦制药飙11%",
            "features": {
                "keywords": [
                    "制药股",
                    "石药集团",
                    "联邦制药",
                    "资金青睐"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "制药股普遍获资金青睐 石药集团上扬2%联邦制药飙11%",
            "scores": {
                "News_content": "制药股普遍获资金青睐 石药集团上扬2%联邦制药飙11%",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "第三家!“A+H”两地上市的CRO企业哪家强？",
            "features": {
                "keywords": [
                    "A+H",
                    "CRO",
                    "上市",
                    "企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "第三家!“A+H”两地上市的CRO企业哪家强？",
            "scores": {
                "News_content": "第三家!“A+H”两地上市的CRO企业哪家强？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "多款新冠疫苗临床数据出炉，T细胞免疫反应为何成为关注热点？",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "临床数据",
                    "T细胞",
                    "免疫反应"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "多款新冠疫苗临床数据出炉，T细胞免疫反应为何成为关注热点？",
            "scores": {
                "News_content": "多款新冠疫苗临床数据出炉，T细胞免疫反应为何成为关注热点？",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "FDA新增II类器械510（k）豁免，510（k）审评通道现代化迈出步伐",
            "features": {
                "keywords": [
                    "FDA",
                    "II类器械",
                    "510(k)",
                    "豁免",
                    "审评通道"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "FDA新增II类器械510（k）豁免，510（k）审评通道现代化迈出步伐",
            "scores": {
                "News_content": "FDA新增II类器械510（k）豁免，510（k）审评通道现代化迈出步伐",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "上市公司正负面新闻2020年7月22日星期三",
            "features": {
                "keywords": [
                    "上市公司",
                    "正负面新闻"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "上市公司正负面新闻2020年7月22日星期三",
            "scores": {
                "News_content": "上市公司正负面新闻2020年7月22日星期三",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2020-07-22",
            "orginal_text": "药明康德（02359-HK）基金股东拟减持 拟减持股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "基金股东",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德（02359-HK）基金股东拟减持 拟减持股份",
            "scores": {
                "News_content": "药明康德（02359-HK）基金股东拟减持 拟减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]